Mylan | LinkedIn
Merck v Mylan: Is Presumption of Invalidity a Defence for Infringement? | Murgitroyd
Mylan Announces Global Settlement and License Agreements with Genentech and Roche on Herceptin®
Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study - The Lancet Digital Health
About Mylan - India
Mylan's EpiPen School Sales Trigger N.Y. Antitrust Probe - Bloomberg
DEF 14A
Mylan | Medicines for Europe
BarentsKrans and Mylan repel Novartis' bid for fingolimod PI - JUVE Patent
Details
Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva -
Merck v Mylan: Is Presumption of Invalidity a Defence for Infringement? | Murgitroyd
image.cfm?name=image-09.jpg&id=536997
Viatris | Global Healthcare Company
Senator's daughter who raised price of EpiPen got paid $19 million salary, perks in 2015 - The Washington Post
image.cfm?name=image-01.jpg&id=536997
image.cfm?name=image-08.jpg&id=536997
SEC Filing | Mylan N.V.
Active Pharmaceutical Ingredients | Viatris
EpiPen dearth shows company and regulator failure
DPT | Contract Pharma
Mylan Specialty | LinkedIn
Viatris | Global Healthcare Company
Impacting Lives for a Better Future
